Skip to main content
Erschienen in: World Journal of Urology 9/2020

18.11.2019 | Original Article

Urinary biomarkers profiles in patients with neurogenic detrusor overactivity according to their neurological condition

verfasst von: Claire Richard, Claude Bendavid, Juliette Hascoet, Quentin Alimi, Zine-eddine Khene, Jacques Kerdraon, Caroline Voiry, Charlène Brochard, Guillaume Bouguen, Laurent Siproudhis, Andrea Manunta, Xavier Gamé, Benoit Peyronnet

Erschienen in: World Journal of Urology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aim of this study was to investigate the disease-specific urinary levels variations of neurotrophins (NGF, BDNF), mediators of inflammation (TGFβ-1, PGE-2) and markers of extracellular matrix alterations (TIMP-2) in patients with multiple sclerosis (MS) spinal cord injury (SCI), or spina bifida (SB), and neurogenic detrusor overactivity (NDO).

Methods

A prospective single-center study was conducted between March 2015 and March 2017. Patients aged over 18 years old, with neurological disease, with a urodynamic diagnosis of NDO were included. The urinary levels of NGF, BDNF, TIMP-2, PGE 2, and TGF-β1 were measured using dedicated ELISA kits.

Results

Forty-one patients were included: 6 with MS, 20 with SCI, and 15 with spina bifida. The average urinary level of NGF/Cr was significantly higher in MS patients compared to other neurologic populations (8 vs. 0.56 vs. 1.25 pg/mg of creatinine; p = 0.001) as well for the average urinary level of BDNF (88.3 vs. 5 vs. 4.8 pg/mg of creatinine; p < 0.0001). SCI patients had a significantly lower level of TGFβ-1 than SB patients (p = 0.04). The urinary level of PGE2 was significantly correlated with the Body Mass Index (r = 0.61; p = 0.0002).

Conclusion

All NDO may not be created equal from the molecular standpoint. Multiple sclerosis patients had higher urinary levels of neurotrophins than in other neurologic populations with NDO. Urinary TGFβ-1, a strong determinant of extracellular matrix, was significantly higher in spina bifida patients compared to SCI patients. These findings underscore the importance of using and interpreting those possible urinary markers in a disease-specific fashion.
Literatur
1.
Zurück zum Zitat Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF et al (2018) An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn 37(3):1152–1161PubMedCrossRef Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF et al (2018) An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn 37(3):1152–1161PubMedCrossRef
2.
Zurück zum Zitat Haab F (2014) Chapter 1: the conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn 33(Suppl 3):S2–S5PubMedCrossRef Haab F (2014) Chapter 1: the conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn 33(Suppl 3):S2–S5PubMedCrossRef
3.
Zurück zum Zitat Ruffion A, de Sèze M, Denys P, Perrouin-Verbe B, Chartier-Kastler E, Groupe d’Etudes de Neuro-Urologie de Langue Française (2007) Groupe d’Etudes de Neuro-Urologie de Langue Française (GENULF) guidelines for the management of spinal cord injury and spina bifida patients. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 17(3):631–633CrossRef Ruffion A, de Sèze M, Denys P, Perrouin-Verbe B, Chartier-Kastler E, Groupe d’Etudes de Neuro-Urologie de Langue Française (2007) Groupe d’Etudes de Neuro-Urologie de Langue Française (GENULF) guidelines for the management of spinal cord injury and spina bifida patients. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 17(3):631–633CrossRef
4.
Zurück zum Zitat Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands J-L et al (2008) Urine in clinical proteomics. Mol Cell Proteom 7(10):1850–1862CrossRef Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands J-L et al (2008) Urine in clinical proteomics. Mol Cell Proteom 7(10):1850–1862CrossRef
5.
Zurück zum Zitat Peyronnet B, Bendavid C, Manunta A, Damphousse M, Cheensse C, Brochard C et al (2015) The role of urinary markers in the assessment and follow-up of lower urinary tract disorders: a literature review. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 25(4):188–199CrossRef Peyronnet B, Bendavid C, Manunta A, Damphousse M, Cheensse C, Brochard C et al (2015) The role of urinary markers in the assessment and follow-up of lower urinary tract disorders: a literature review. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 25(4):188–199CrossRef
6.
Zurück zum Zitat Top T, Sekerci CA, Isbilen-Basok B, Tanidir Y, Tinay I, Isman FK et al (2017) The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. Neurourol Urodyn 36(7):1896–1902PubMedCrossRef Top T, Sekerci CA, Isbilen-Basok B, Tanidir Y, Tinay I, Isman FK et al (2017) The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. Neurourol Urodyn 36(7):1896–1902PubMedCrossRef
7.
Zurück zum Zitat Liu H-T, Chancellor MB, Kuo H-C (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56(4):700–706PubMedCrossRef Liu H-T, Chancellor MB, Kuo H-C (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56(4):700–706PubMedCrossRef
8.
Zurück zum Zitat Yamauchi H, Akino H, Ito H, Aoki Y, Nomura T, Yokoyama O (2010) Urinary prostaglandin E2 was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. Urology 76(5):1267.e13–1267.e19CrossRef Yamauchi H, Akino H, Ito H, Aoki Y, Nomura T, Yokoyama O (2010) Urinary prostaglandin E2 was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. Urology 76(5):1267.e13–1267.e19CrossRef
9.
Zurück zum Zitat Owens T (2003) The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 16(3):259–265PubMedCrossRef Owens T (2003) The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 16(3):259–265PubMedCrossRef
10.
Zurück zum Zitat Neuhaus O, Archelos JJ, Hartung H-P (2003) Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24(3):131–138PubMedCrossRef Neuhaus O, Archelos JJ, Hartung H-P (2003) Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24(3):131–138PubMedCrossRef
11.
Zurück zum Zitat Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C et al (2005) Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 62(2):176–182PubMedCrossRef Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C et al (2005) Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 62(2):176–182PubMedCrossRef
12.
Zurück zum Zitat Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2006) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 27(Suppl 1):S1–S7PubMedCrossRef Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2006) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 27(Suppl 1):S1–S7PubMedCrossRef
13.
Zurück zum Zitat Kalinowska-Lyszczarz A, Losy J (2012) The role of neurotrophins in multiple sclerosis—pathological and clinical implications. Int J Mol Sci 13(12):13713–13725PubMedPubMedCentralCrossRef Kalinowska-Lyszczarz A, Losy J (2012) The role of neurotrophins in multiple sclerosis—pathological and clinical implications. Int J Mol Sci 13(12):13713–13725PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53(3):292–304PubMedCrossRef Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53(3):292–304PubMedCrossRef
15.
Zurück zum Zitat Bazhenov IV, Filippova ES, Bazarnyi VV, Sazonov SV, Volkova LI, Zaitseva LN (2019) Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis. Urol Mosc Russ 1999 3:44–48 Bazhenov IV, Filippova ES, Bazarnyi VV, Sazonov SV, Volkova LI, Zaitseva LN (2019) Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis. Urol Mosc Russ 1999 3:44–48
16.
Zurück zum Zitat Şekerci ÇA, Işbilen B, Işman F, Akbal C, Şimşek F, Tarcan T (2014) Urinary NGF, TGF-β1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia. J Urol 191(1):199–205PubMedCrossRef Şekerci ÇA, Işbilen B, Işman F, Akbal C, Şimşek F, Tarcan T (2014) Urinary NGF, TGF-β1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia. J Urol 191(1):199–205PubMedCrossRef
17.
Zurück zum Zitat Peyronnet B, Even A, Capon G, De Seze M, Hascoet J, Biardeau X et al (2018) Intradetrusor injections of botulinum toxin A in adults with spinal dysraphism. J Urol 200(4):875–880PubMedCrossRef Peyronnet B, Even A, Capon G, De Seze M, Hascoet J, Biardeau X et al (2018) Intradetrusor injections of botulinum toxin A in adults with spinal dysraphism. J Urol 200(4):875–880PubMedCrossRef
18.
Zurück zum Zitat Fry CH, Kitney DG, Paniker J, Drake MJ, Kanai A, Andersson K-E (2018) Fibrosis and the bladder, implications for function ICI-RS 2017. Neurourol Urodyn 37(S4):S7–S12PubMedCrossRef Fry CH, Kitney DG, Paniker J, Drake MJ, Kanai A, Andersson K-E (2018) Fibrosis and the bladder, implications for function ICI-RS 2017. Neurourol Urodyn 37(S4):S7–S12PubMedCrossRef
19.
Zurück zum Zitat Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson K-E (2008) Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int 102(6):741–746PubMedCrossRef Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson K-E (2008) Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int 102(6):741–746PubMedCrossRef
20.
Zurück zum Zitat Beqaj SH, Donovan JL, Liu DB, Harrington DA, Alpert SA, Cheng EY (2005) Role of basic fibroblast growth factor in the neuropathic bladder phenotype. J Urol 174(4 Pt 2):1699–1703PubMedCrossRef Beqaj SH, Donovan JL, Liu DB, Harrington DA, Alpert SA, Cheng EY (2005) Role of basic fibroblast growth factor in the neuropathic bladder phenotype. J Urol 174(4 Pt 2):1699–1703PubMedCrossRef
21.
Zurück zum Zitat Janzen J, Vuong PN, Bersch U, Michel D, Zaech GA (1998) Bladder tissue biopsies in spinal cord injured patients: histopathologic aspects of 61 cases. Neurourol Urodyn 17(5):525–530PubMedCrossRef Janzen J, Vuong PN, Bersch U, Michel D, Zaech GA (1998) Bladder tissue biopsies in spinal cord injured patients: histopathologic aspects of 61 cases. Neurourol Urodyn 17(5):525–530PubMedCrossRef
22.
Zurück zum Zitat Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119PubMedCrossRef Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119PubMedCrossRef
23.
Zurück zum Zitat Oztekin CV, Kaya-Sezginer E, Yilmaz-Oral D, Gur S (2018) Male urogenital disorders and metabolic syndrome: possible links, characteristics and potential treatment strategies. Curr Pharm Des 24(9):1019–1033PubMedCrossRef Oztekin CV, Kaya-Sezginer E, Yilmaz-Oral D, Gur S (2018) Male urogenital disorders and metabolic syndrome: possible links, characteristics and potential treatment strategies. Curr Pharm Des 24(9):1019–1033PubMedCrossRef
24.
Zurück zum Zitat He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S (2016) Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis 19(1):7–13PubMedCrossRef He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S (2016) Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis 19(1):7–13PubMedCrossRef
25.
Zurück zum Zitat Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA (2014) What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Neurourol Urodyn 33(5):602–605PubMedPubMedCentralCrossRef Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA (2014) What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Neurourol Urodyn 33(5):602–605PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Gamper M, Moser R, Viereck V (2017) Have we been led astray by the NGF biomarker data?: accurate NGF Assay? Neurourol Urodyn 36(1):203–204PubMedCrossRef Gamper M, Moser R, Viereck V (2017) Have we been led astray by the NGF biomarker data?: accurate NGF Assay? Neurourol Urodyn 36(1):203–204PubMedCrossRef
Metadaten
Titel
Urinary biomarkers profiles in patients with neurogenic detrusor overactivity according to their neurological condition
verfasst von
Claire Richard
Claude Bendavid
Juliette Hascoet
Quentin Alimi
Zine-eddine Khene
Jacques Kerdraon
Caroline Voiry
Charlène Brochard
Guillaume Bouguen
Laurent Siproudhis
Andrea Manunta
Xavier Gamé
Benoit Peyronnet
Publikationsdatum
18.11.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 9/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-03016-x

Weitere Artikel der Ausgabe 9/2020

World Journal of Urology 9/2020 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.